Compare Neurocrine Biosciences Inc (NBIX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Energy Select Sector SPDR Fund — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Energy Select Sector SPDR Fund trades at $65.63. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | XLE | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | — |
52-Week High | $185.50 | $65.31 |
52-Week Low | $123.10 | $42.61 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
XLE trades at $64.78, up 1.12% with strong bullish technical signals from moving averages. The ETF benefits from oil price strength above $100/barrel and geopolitical tensions in the Middle East. Recent performance shows XLE gained 7.4% in August, leading sector ETFs. Technical indicators show RSI at 78.15 suggests overbought conditions while ADX indicates strong trend momentum.
Outlook remains positive given energy sector tailwinds from supply constraints and winter demand, though elevated oil prices create both opportunity and volatility risk. The ETF's concentrated holdings in major energy companies provide leveraged exposure to crude price movements, with valuations reflecting long-term oil prices below current spot levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
